Effects of rosiglitazone on cardiac function in CAPD patients: a tissue Doppler study.
BACKGROUND
Insulin resistance was an independent predictor of cardiovascular mortality in uremic patients without diabetes. Rosiglitazone (ROS) improves insulin sensitivity in the liver, muscle, and adipose tissue. We prospectively investigated the effects of ROS on cardiac functions by standard (SDE) and tissue Doppler echocardiography (TDI) in continuous ambulatory peritoneal dialysis (CAPD) patients.


METHODS
A total of 24 CAPD patients (13 males, 11 females; mean age 42.2 +/- 14.8 years) were included. Routine blood samples were examined. Left and right ventricular functions were assessed, and myocardial performance index (MPI) was calculated by SDE and TDI at baseline and after 12-month ROS therapy. Left and right atrial volumes were measured and indexed to body surface area.


RESULTS
When compared with baseline, after 12 months of ROS treatment, it was shown that early (E) and late (A) diastolic velocities of atrioventricular valves, E/A ratio, mitral E-wave deceleration time (DT), isovolumetric relaxation time (IVRT), and MPI were similar (p > 0.05). Also, no significant changes were detected in LV dimensions, LV mass index, LVEF, LA volume index, or RA volume index measured by SDE before and after ROS therapy (p > 0.05). Left and right ventricular function parameters measured by TDI including Sm, Em, Am, Em/Am ratio, E/Em ratio, and MPI were similar.


CONCLUSIONS
It was found that there was no negative effect of long-term ROS therapy on cardiac functions measured by SDE and TDI in CAPD patients.
Akcay
Ahmet
A
Faculty of Medicine, Department of Cardiology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey. dr.akcay@yahoo.com.tr
Acar
Gurkan
G
Sokmen
Abdullah
A
Sokmen
Gulizar
G
Dogan
Ekrem
E
Sayarlioglu
Hayriye
H
Citirik
Cagatay
C
Ucar
Mehmet Ali
MA
Tuncer
Cemal
C
D000328:Adult; D001783:Blood Flow Velocity; D015331:Cohort Studies; D018619:Echocardiography, Doppler, Pulsed / Q000379:methods*; D005260:Female; D006334:Heart Function Tests; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods*; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D000077154:Rosiglitazone; D016019:Survival Analysis; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D018497:Ventricular Dysfunction, Right / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality
D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone